hVIVO shares surge as contract wins build investor confidence

Shares in hVIVO PLC (AIM:HVO), the human challenge trial specialist, were up 7% to 7.99p, extending a recovery that has seen the stock gain around 25% since the start of the year, after the latest in a run of contract announcements. The catalyst for today's move is the signing of a £6 million clinical trial agreement to conduct an influenza human challenge trial for an unnamed biopharmaceutical company, the latest in a sequence of deals that analysts at Cavendish say is providing a "step change" to revenue visibility for 2026.